Title :

A comprehensive overview of promising biomarkers in stage II colorectal cancer

Author(s) :

Parent, Pauline [Auteur]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Cohen, Romain [Auteur]
CHU Saint-Antoine [AP-HP]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Université de Lille
Rassy, Elie [Auteur]
Institut Gustave Roussy [IGR]
Université Saint-Joseph de Beyrouth [USJ]
Svrcek, Magali [Auteur]
CHU Saint-Antoine [AP-HP]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Université de Lille
Taieb, Julien [Auteur]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Université Sorbonne Paris Cité [USPC]
André, Thierry [Auteur]
CHU Saint-Antoine [AP-HP]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Université de Lille
Turpin, Anthony [Auteur correspondant]
Hétérogénéité, Plasticité et Résistance aux Thérapies des Cancers = Cancer Heterogeneity, Plasticity and Resistance to Therapies - UMR 9020 - U 1277 [CANTHER]
Centre Hospitalier Régional Universitaire [CHU Lille] [CHRU Lille]
Hôpital Européen Georges Pompidou [APHP] [HEGP]
Université Sorbonne Paris Cité [USPC]
Hôpital Claude Huriez [Lille]

Journal title :

Cancer Treatment Reviews

Pages :

102059 -

Publisher :

WB Saunders

Publication date :

2020-08-31

ISSN :

0305-7372

English keyword(s) :

Adjuvant chemotherapy
Artificial intelligence
Carcinoembryonic antigen
Circulating Tumor DNA
Colorectal cancer
Immunoscore

HAL domain(s) :

Sciences du Vivant [q-bio]

English abstract : [en]

Colon cancer (CC) has the highest incidence rate among gastrointestinal cancers and ranks the third in mortality among all cancers, which contributes to the current CC burden and constitutes a major public health issue. ...
Show more >Colon cancer (CC) has the highest incidence rate among gastrointestinal cancers and ranks the third in mortality among all cancers, which contributes to the current CC burden and constitutes a major public health issue. While therapeutic strategies for stage I, III, and IV CC are standardized, those for stage II CC remain debatable. The choice of adjuvant chemotherapy for patients with stage II CC depends on stage (pT4) and grade (high) of the disease, the presence of venous, perinervous, and/or lymphatic emboli, or the need of suboptimal surgery (tumor with initial occlusion or perforation needing emergency surgeries, <12 lymph nodes harvested). Several prognostic factors that have been validated in retrospective studies can potentially define a population of CC patients at low and high-risk for reccurence. The role of biomarkers is becoming increasingly important for the future personalized treatment options. We conducted a systematic overview of potential prognostic biomarkers with possible clinical implications in stage II CC.Show less >

Language :

Anglais

Peer reviewed article :

Oui

Audience :

Internationale

Popular science :

Non

Collections :

• Cancer Heterogeneity, Plasticity and Resistance to Therapies (CANTHER) - UMR 9020 - UMR 1277

Source :

Harvested from HAL